China
· Delayed Price · Currency is CNY Dizal (Jiangsu) Pharmaceutical Statistics
Total Valuation
Dizal (Jiangsu) Pharmaceutical has a market cap or net worth of CNY 14.87 billion. The enterprise value is 14.74 billion.
| Market Cap | 14.87B |
| Enterprise Value | 14.74B |
Important Dates
The next estimated earnings date is Tuesday, October 29, 2024.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Dizal (Jiangsu) Pharmaceutical has 415.65 million shares outstanding. The number of shares has increased by 1.30% in one year.
| Shares Outstanding | 415.65M |
| Shares Change (YoY) | +1.30% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 3.20% |
| Owned by Institutions (%) | 19.38% |
| Float | 121.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 49.86 |
| PB Ratio | 24.42 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.71 |
| EV / Sales | 50.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.97 |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 110.41.
| Current Ratio | 1.87 |
| Quick Ratio | 1.69 |
| Debt / Equity | 110.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.79 |
| Interest Coverage | -73.28 |
Financial Efficiency
Return on equity (ROE) is -104.24% and return on invested capital (ROIC) is -48.20%.
| Return on Equity (ROE) | -104.24% |
| Return on Assets (ROA) | -40.12% |
| Return on Capital (ROIC) | -48.20% |
| Revenue Per Employee | 365,352 |
| Profits Per Employee | -1.16M |
| Employee Count | 581 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.16% in the last 52 weeks. The beta is 0.16, so Dizal (Jiangsu) Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +12.16% |
| 50-Day Moving Average | 38.18 |
| 200-Day Moving Average | 40.85 |
| Relative Strength Index (RSI) | 37.99 |
| Average Volume (20 Days) | 1,354,432 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dizal (Jiangsu) Pharmaceutical had revenue of CNY 294.84 million and -938.21 million in losses. Loss per share was -2.28.
| Revenue | 294.84M |
| Gross Profit | 282.41M |
| Operating Income | -1.09B |
| Pretax Income | -1.03B |
| Net Income | -938.21M |
| EBITDA | -1.05B |
| EBIT | -1.09B |
| Loss Per Share | -2.28 |
Balance Sheet
The company has 827.93 million in cash and 686.21 million in debt, giving a net cash position of 141.72 million or 0.34 per share.
| Cash & Cash Equivalents | 827.93M |
| Total Debt | 686.21M |
| Net Cash | 141.72M |
| Net Cash Per Share | 0.34 |
| Equity (Book Value) | 621.51M |
| Book Value Per Share | 1.47 |
| Working Capital | 475.90M |
Cash Flow
In the last 12 months, operating cash flow was -828.50 million and capital expenditures -40.20 million, giving a free cash flow of -868.70 million.
| Operating Cash Flow | -828.50M |
| Capital Expenditures | -40.20M |
| Free Cash Flow | -868.70M |
| FCF Per Share | -2.09 |
Margins
| Gross Margin | 95.78% |
| Operating Margin | -368.37% |
| Pretax Margin | -347.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -294.64% |
Dividends & Yields
Dizal (Jiangsu) Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.30% |
| Shareholder Yield | -1.30% |
| Earnings Yield | -6.38% |
| FCF Yield | -5.84% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |